Altered gene expression by cisplatin in a human squamous cell lung carcinoma cell line

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3235-3243

  Yatomi, Mari ^a   Takiguchi, Yuichi ^a   Asaka Amano, Yoshiko ^a   Arai, Makoto ^a   Tada, Yuji ^a   Kurosu, Katsushi ^a   Sakao, Seiichiro ^a   Kasahara, Yasunori ^a   Tanabe, Nobuhiro ^a   Tatsumi, Koichiro ^a   Seki, Naohiko ^a   Kuriyama, Takayuki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Cisplatin; DNA microarray; Lung cancer; Small interference RNA

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CYTOTOXICITY; DNA METABOLISM; DNA REPAIR; DRUG INHIBITION; DRUG MECHANISM; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; LUNG CARCINOMA; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 35349004163     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang K-Y, Schlom J and Hodge JW: Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 12: 1897-1905, 2006.
2. van Waardenburg RCAM, de Jong LA, van Delft F, van Eijndhoven MAJ, Bohlander M, Bjornsti M-A, Brouwer J and Schellens JHM: Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons. Mol Cancer Therapeut 3: 393-402, 2004.
3. Alvarez MV, Cobreros G, Heras A and Lopez Zumel MC: Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer. Br J Cancer 37(suppl): 68-72, 1978.
4. Nakamoto S, Mitsuhashi N, Takahashi T, Sakurai H and Niibe H: An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro. Int J Radiat Biol 70: 747-753, 1996.
5. Flentje M, Eble M, Haner U, Trinh S and Wannenmacher M: Additive effects of cisplatin and radiation in human tumor cells under oxic conditions. Radiother Oncol 24: 60-63, 1992.
6. Gorodetsky R, Levy-Agababa F, Mou X and Vexler AM: Combination of cisplatin and radiation in cell culture: effect of duration of exposure to drug and timing of irradiation. Int J Cancer 75: 635-642, 1998.
7. Asaka-Amano Y, Takiguchi Y, Yatomi M, Kurosu K, Kasahara Y, Tanabe N, Tatsumi K and Kuriyama T: Effect of treatment schedule on the interaction of Cisplatin and radiation in human lung cancer cells. Radiat Res 167: 637-644, 2007.
8. Lawrence TS, Blackstock AW and McGinn C: The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13: 13-21, 2003.
9. Gregoire V, Van NT, Stephens LC, Brock WA, Milas L, Plunkett W and Hittelman WN: The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 54: 6201-6209, 1994.
10. Lockhart AC, Tirona RG and Kim RB: Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Therapeut 2: 685-698, 2003.
11. Liang X-J, Taylor B, Cardarelli C, Yin J-J, Annereau J-P, Garfield S, Wincovitch S, Szakacs G, Gottesman MM and Aszalos A: Different roles for K+ channels in cisplatin-resistant cell lines argue against a critical role for these channels in cisplatin resistance. Anticancer Res 25: 4113-4122, 2005.
12. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.
13. Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis 21: 485-495, 2000.
14. Osbild S, Brault L, Battaglia E and Bagrel D: Resistance to cisplatin and adriamycin is associated with the inhibition of glutathione efflux in MCF-7-derived cells. Anticancer Res 26: 3595-3600, 2006.
15. Lin X and Howell SB: DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Therapeut 5: 1239-1247, 2006.
16. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
17. Kornberg L: Ad-fRNK and Ad-p53 cooperate to augment drug-induced death of a transformed cell line. Anticancer Res 26: 3025-3031, 2006.
18. Mohr S, Leikauf GD, Keith Gr and Rihn BH: Microarrays as cancer keys: an array of possibilities. J Clin Oncol 20: 3165-3175, 2002.
19. Arai M, Yokosuka O, Hirasawa Y, Fukai K, Chiba T, Imazeki F, Kanda T, Yatomi M, Takiguchi Y, Seki N, Saisho H and Ochiai T: Sequential gene expression changes in cancer cell lines after treatment with the demethylation agent 5-aza-2′-deoxycytidine. Cancer 106: 2514-2525, 2006.
20. Macgregor PF and Squire JA: Application of microarrays to the analysis of gene expression in cancer. Clin Chem 48: 1170-1177, 2002.
21. Qin LF, Lee TKW and Ng IOL: Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment. Life Sci 70: 1677-1690, 2002.
22. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH and Heber D: Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 22: 663-670, 2003.
23. Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun HJ and Fayyazi A: Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br J Cancer 91: 589-598, 2004.
24. Kerley-Hamilton JS, Pike AM, Li N, DiRenzo J and Spinella MJ: A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene 24: 6090-6100, 2005.
25. Fish RJ and Kruithof EKO: Evidence for serpinB2-independent protection from TNF-alpha-induced apoptosis. Exp Cell Res 312: 350-361, 2006.
26. Dickinson JL, Bates EJ, Ferrante A and Antalis TM: Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 270: 27894-27904, 1995.
27. Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, Harrich D and Suhrbier A: Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 23: 6520-6532, 2003.
28. Chang C-C, Shih J-Y, Jeng Y-M, Su J-L, Lin B-Z, Chen S-T, Chau Y-P, Yang P-C and Kuo M-L: Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 96: 364-375, 2004.
29. Lin B-R, Chang C-C, Che T-F, Chen S-T, Chen RJ-C, Yang C-Y, Jeng Y-M, Liang J-T, Lee P-H, Chang K-J, Chau Y-P and Kuo M-L: Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterol 128: 9-23, 2005.
30. Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kisiel N, Diegelman P, Chen Y and Pendyala L: Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol Cancer Therapeut 3: 813-822, 2004.
31. Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S and Sato M: Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64: 5461-5470, 2004.
32. Hofbauer K-H, Gess B, Lohaus C, Meyer HE, Katschinski D and Kurtz A: Oxygen tension regulates the expression of a group of procollagen hydroxylases. Eur J Biochem / FEBS 270: 4515-4522, 2003.
33. Elkind MM: DNA damage and cell killing. Cause and effect? Cancer 56: 2351-2363, 1985.
34. Maity A, Kao GD, Muschel RJ and McKenna WG: Potential molecular targets for manipulating the radiation response. Int J Radiat Oncol Biol Phys 37: 639-653, 1997.
35. Watanabe M, Hitomi M, van der Wee K, Rothenberg F, Fisher SA, Zucker R, Svoboda KK, Goldsmith EC, Heiskanen KM and Nieminen AL: The pros and cons of apoptosis assays for use in the study of cells, tissues, and organs. Microsc Microanal 8: 375-391, 2002.
36. Howe O, O'Malley K, Lavin M, Gardner RA, Seymour C, Lyng F, Mulvin D, Quinlan DM and Mothersill C: Cell death mechanisms associated with G2 radiosensitivity in patients with prostate cancer and benign prostatic hyperplasia. Radiat Res 164: 627-634, 2005.